ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1897

the Ferritin to ESR Ratio: A Simple Measure to Distinguish Macrophage Activation Syndrome from Systemic Arthritis Flare

Esraa M. A. Eloseily1,2, Francesca Minoia3, Timothy Beukelman2, Angelo Ravelli4 and Randy Q. Cron2, 1Pediatrics, Assiut University, Assiut, Egypt, 2Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Istituto Giannina Gaslini, Genoa, Italy, 4University of Genova, Genova, Italy

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Systemic JIA and macrophage activation syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Autoinflammatory Diseases

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Macrophage activation syndrome (MAS) is a life threatening complication of systemic juvenile idiopathic arthritis (sJIA). As MAS often shares clinical and laboratory features with sJIA disease flare, it can be difficult to distinguish. For new sJIA diagnoses, MAS associated with sJIA (sJIA-MAS) also has to be discerned from infection. A previous study suggested a serum ferritin to erythrocyte sedimentation rate (ESR) ratio of >80 could identify MAS among a small cohort of children with new-onset sJIA (J Rheumatol. 2013;40:1191). As a simple and quick tool, the ferritin to ESR ratio was explored to differentiate sJIA-MAS from active sJIA without MAS (flare), and from hospitalized febrile patients with systemic infections (SI).

Methods:

Data was reviewed from a multinational study of patients with sJIA-MAS (n=362), sJIA flare (n=404), and SI (n=345) (Arthritis Rheumatol. 2014;66:3160). Patients without documented ESR or ferritin were excluded, leaving 262 sJIA-MAS, 262 sJIA flare, and 93 SI. Receiver operating characteristic curves for ferritin/ESR were constructed, and areas under the curves (AUC) were calculated with 95% confidence intervals. The Youden index was used to determine the optimal ferritin/ESR cut-point.

Results:

For the ferritin/ESR ratio, comparing sJIA-MAS vs. sJIA flare, a cut off value of 21.5 had a sensitivity of 0.82 and specificity of 0.78 (AUC: 0.87 [0.84-0.90]). Comparing the ratio in sJIA-MAS cases vs. SI, a cut off value of 11.3 had a sensitivity of 0.91 and specificity of 0.93 (AUC: 0.95 [0.92-0.97]). Comparing sJIA-MAS cases vs. all others (sJIA flare & SI combined), a cut off value of 21.5 had a sensitivity of 0.82 and specificity of 0.83. (AUC: 0.89 [0.87-0.92]).

Conclusion:

The ferritin/ESR ratio with a cut off value of 21.5 accurately distinguishes sJIA-MAS from sJIA flare. This discriminatory ratio performs comparably to and is less complicated than the recent MAS in sJIA classification criteria (Ann Rheum Dis. 2016;75:481). In distinguishing sJIA-MAS from hospitalized infection, a ferritin/ESR ratio of 11.3 was a powerful tool with high sensitivity and specificity. The ferritin/ESR ratio is a quick and simple measure for distinguishing sJIA-MAS from sJIA flare and infection. Future studies should explore the measure in different MAS cohorts.

 


Disclosure: E. M. A. Eloseily, None; F. Minoia, None; T. Beukelman, UCB, 5,Novartis Pharmaceutical Corporation, 5; A. Ravelli, None; R. Q. Cron, SOBI, 5.

To cite this abstract in AMA style:

Eloseily EMA, Minoia F, Beukelman T, Ravelli A, Cron RQ. the Ferritin to ESR Ratio: A Simple Measure to Distinguish Macrophage Activation Syndrome from Systemic Arthritis Flare [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-ferritin-to-esr-ratio-a-simple-measure-to-distinguish-macrophage-activation-syndrome-from-systemic-arthritis-flare/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-ferritin-to-esr-ratio-a-simple-measure-to-distinguish-macrophage-activation-syndrome-from-systemic-arthritis-flare/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology